Overview
Ceftibuten is a third-generation cephalosporin antibiotic that is orally-administered. It is typically used to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis.
Indication
Indicated for the treatment of acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis.
Associated Conditions
- Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB)
- Acute Otitis Media (AOM)
- Acute Sinusitis
- Acute Tracheobronchitis
- Bacterial Infections
- Bacterial Pneumonia
- Lower Respiratory Tract Infection (LRTI)
- Lower Respiratory Tract Infection (LRTI) caused by susceptible bacteria
- Pharyngitis
- Skin and Soft Tissue Infections (SSTIs)
- Streptococcal Pharyngitis
- Superinfection bacterial
- Tonsillitis
- Tonsillitis streptococcal
- Upper Respiratory Tract Infection
- Upper Respiratory Tract Infection caused by susceptible bacteria
- Urinary Tract Infection caused by susceptible bacteria
- Bacterial otitis media
- Uncomplicated Lower Respiratory Tract Infection (LRTI)
- Uncomplicated Upper Respiratory Tract Infection
- Uncomplicated Urethritis gonococcal
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2024/12/13 | Phase 1 | Active, not recruiting | |||
2024/10/30 | Phase 1 | Completed | |||
2024/09/19 | Phase 1 | Completed | |||
2023/12/05 | Phase 1 | Completed | |||
2023/10/12 | Phase 1 | Recruiting | |||
2022/09/26 | Phase 1 | Completed | |||
2022/09/06 | Phase 1 | Completed | |||
2022/08/04 | Phase 1 | Completed | |||
2008/07/29 | Phase 3 | Terminated | IRCCS Burlo Garofolo |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
No TGA approvals found for this drug. |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
---|---|---|---|---|---|
No Health Canada approvals found for this drug. |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
---|---|---|---|---|---|
No CIMA AEMPS (Spain) approvals found for this drug. |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Philippines FDA approvals found for this drug. |
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Saudi SFDA approvals found for this drug. |
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Malaysia NPRA approvals found for this drug. |
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
---|---|---|---|---|---|
No UK EMC drug information found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.